Sou Hu Cai Jing·2025-07-26 19:26Group 1 - Fosun Pharma's stock price increased to 26.66 CNY as of July 25, 2025, reflecting a 1.14% rise from the previous week [1] - The company's market capitalization is currently 71.194 billion CNY, ranking 6th in the chemical pharmaceutical sector and 210th in the A-share market [1] Group 2 - Fosun Pharma announced the establishment of a new subsidiary, Xingrui Jingxuan, with an initial registered capital of 133.5 million CNY, aiming to invest in the nuclear medicine sector [2] - Fosun Pharma will hold approximately 89.89% of the new company, which will focus on integrated diagnostic and therapeutic nuclear medicine products in the oncology field [2] Group 3 - The company completed its A-share and H-share repurchase plans, with a total repurchase amount of approximately 348.36 million CNY for A-shares and 47.84 million HKD for H-shares [3] - The A-share repurchase involved 14,228,552 shares, accounting for 0.5328% of the total share capital, while the H-share repurchase involved 3,410,500 shares, accounting for 0.1277% of the total share capital [3] Group 4 - Fosun Pharma will distribute a cash dividend of 0.32 CNY per share (pre-tax) for the 2024 fiscal year, with a total expected payout of approximately 844.66 million CNY [4] - The ex-dividend date is set for August 4, 2025, with the record date on August 1, 2025 [4] Group 5 - The legal opinion regarding the differentiated profit distribution plan was issued by Guohao Law Firm, confirming the legality of the cash dividend distribution [5] - The company has repurchased a total of 19,906,252 A-shares, which do not have profit distribution rights [5]